In patients with metastatic colorectal cancer, BRAF-mut portends a significantly worse prognosis [11,28,29,30], and is associated with both a lack of response to anti-EGFR therapy [31] and a decreased resectability rate of recurrence after the initial resection of CLMs [32]. This evidence concerns the gene EGFR and metastatic colorectal cancer.